Cytosorbents Corp Company Profile (NASDAQ:CTSO)

About Cytosorbents Corp (NASDAQ:CTSO)

Cytosorbents Corp logoCytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTSO
  • CUSIP: N/A
  • Web:
  • Market Cap: $151.78 million
  • Outstanding Shares: 28,108,000
Average Prices:
  • 50 Day Moving Avg: $4.25
  • 200 Day Moving Avg: $4.95
  • 52 Week Range: $3.30 - $6.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.83 million
  • Price / Sales: 14.02
  • Book Value: ($0.06) per share
  • Price / Book: -90.00
  • EBIDTA: ($10,770,000.00)
  • Net Margins: -44.26%
  • Return on Assets: -61.47%
  • Debt-to-Equity Ratio: -2.34%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.88%
  • Average Volume: 125,376 shs.
  • Beta: -0.59
  • Short Ratio: 9.19

Frequently Asked Questions for Cytosorbents Corp (NASDAQ:CTSO)

What is Cytosorbents Corp's stock symbol?

Cytosorbents Corp trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents Corp's earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.06. The firm earned $3.11 million during the quarter, compared to analysts' expectations of $2.99 million. View Cytosorbents Corp's Earnings History.

Where is Cytosorbents Corp's stock going? Where will Cytosorbents Corp's stock price be in 2017?

6 analysts have issued 12-month price objectives for Cytosorbents Corp's stock. Their forecasts range from $7.00 to $24.00. On average, they expect Cytosorbents Corp's stock price to reach $12.38 in the next year. View Analyst Ratings for Cytosorbents Corp.

What are analysts saying about Cytosorbents Corp stock?

Here are some recent quotes from research analysts about Cytosorbents Corp stock:

  • 1. Maxim Group analysts commented, "Recall back in June of 2016 CytoSorbents entered into a Loan and Security Agreement with Western Alliance Bank, securing an initial $5 million, 4-year term loan with the option of another $5M. On June 30, 2017, the Company elected to drawdown the additional $5 million of funding available under the Loan and Security Agreement, bringing its total borrowings under the facility to $10 million." (7/5/2017)
  • 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)

Who are some of Cytosorbents Corp's key competitors?

Who are Cytosorbents Corp's key executives?

Cytosorbents Corp's management team includes the folowing people:

  • Al Kraus, Chairman of the Board
  • Phillip P. Chan M.D., Ph.D., President, Chief Executive Officer, Director
  • Kathleen P. Bloch CPA, Chief Financial Officer
  • Vincent J. Capponi, Chief Operating Officer
  • Eric G. Mortensen, Chief Medical Officer
  • Michael G. Bator, Director
  • James T. Gunton, Independent Director
  • Edward R. Jones M.D., Independent Director
  • Alan D. Sobel, Independent Director

Who owns Cytosorbents Corp stock?

Cytosorbents Corp's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Skylands Capital LLC (2.11%). Company insiders that own Cytosorbents Corp stock include Al Kraus, Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents Corp.

Who bought Cytosorbents Corp stock? Who is buying Cytosorbents Corp stock?

Cytosorbents Corp's stock was acquired by a variety of institutional investors in the last quarter, including Skylands Capital LLC. Company insiders that have bought Cytosorbents Corp stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents Corp.

How do I buy Cytosorbents Corp stock?

Shares of Cytosorbents Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytosorbents Corp's stock price today?

One share of Cytosorbents Corp stock can currently be purchased for approximately $5.40.

MarketBeat Community Rating for Cytosorbents Corp (NASDAQ CTSO)
Community Ranking:  4.8 out of 5 (   )
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cytosorbents Corp (NASDAQ:CTSO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.38 (129.17% upside)

Analysts' Ratings History for Cytosorbents Corp (NASDAQ:CTSO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Maxim GroupSet Price TargetBuy$10.00MediumView Rating Details
6/7/2017Cowen and CompanyInitiated CoverageOutperform$7.00HighView Rating Details
5/15/2017B. RileyReiterated RatingBuy$11.25LowView Rating Details
5/9/2017AegisReiterated RatingBuy$9.00HighView Rating Details
3/6/2017HC WainwrightBoost Price TargetBuy$11.50 -> $13.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/AView Rating Details
10/29/2015WBB SecuritiesUpgradeSpeculative Buy -> Buy$13.00N/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Cytosorbents Corp (NASDAQ:CTSO)
Earnings by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Earnings History by Quarter for Cytosorbents Corp (NASDAQ CTSO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.11)($0.05)$2.99 million$3.11 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.10)($0.16)$2.59 million$3.08 millionViewN/AView Earnings Details
11/7/2016Q3($0.11)($0.11)$2.35 million$2.14 millionViewListenView Earnings Details
8/9/2016Q216($0.09)($0.12)$2.18 million$1.90 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.08)$1.51 million$1.76 millionViewN/AView Earnings Details
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details
8/13/2015Q215($0.11)$0.05$0.92 million$0.96 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.11)$0.80 million$0.72 millionViewListenView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.13 million$1.03 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.01)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytosorbents Corp (NASDAQ:CTSO)
2017 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.11)($0.11)($0.11)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.08)($0.07)($0.08)
Q4 20172($0.09)($0.08)($0.09)
(Data provided by Zacks Investment Research)


Dividend History for Cytosorbents Corp (NASDAQ:CTSO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cytosorbents Corp (NASDAQ:CTSO)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 8.75%
Insider Trades by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Institutional Ownership by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Insider Trades by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Eric R MortensenInsiderBuy2,500$4.04$10,100.00View SEC Filing  
6/9/2017Michael G. BatorDirectorBuy1,500$4.12$6,180.00View SEC Filing  
6/8/2017Phillip P. ChanInsiderBuy3,700$4.00$14,800.00View SEC Filing  
6/8/2017Vincent CapponiCOOBuy2,500$4.00$10,000.00View SEC Filing  
6/5/2017Phillip P. ChanInsiderBuy6,300$4.00$25,200.00View SEC Filing  
5/15/2017Kathleen P. BlochCFOBuy1,000$4.34$4,340.00View SEC Filing  
12/9/2016Phillip P. ChanInsiderBuy4,600$5.40$24,840.00View SEC Filing  
12/6/2016Kathleen P BlochCFOBuy1,000$4.83$4,830.00View SEC Filing  
8/24/2016Phillip P ChanInsiderBuy5,000$4.89$24,450.00View SEC Filing  
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.00View SEC Filing  
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.00View SEC Filing  
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.28View SEC Filing  
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.00View SEC Filing  
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.00View SEC Filing  
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cytosorbents Corp (NASDAQ:CTSO)
Latest Headlines for Cytosorbents Corp (NASDAQ:CTSO)
DateHeadline logoCytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR - PR Newswire (press release) - July 17 at 5:56 PM logoCytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR - July 17 at 12:12 PM logoCytoSorbents Awarded $1 Million STTR Phase II Contract To ... - PR Newswire (press release) - July 14 at 4:52 AM logoCytosorbents (CTSO) Secures $1M STTR Phase II Contract To ... - - July 13 at 6:51 PM logo$3.29 Million in Sales Expected for Cytosorbents Corporation (CTSO) This Quarter - July 9 at 10:00 AM logoZacks: Brokerages Anticipate Cytosorbents Corporation (CTSO) Will Announce Earnings of -$0.06 Per Share - July 7 at 8:55 AM logoCytoSorbents receives additional $5M in non-dilutive debt financing from Bridge Bank - July 5 at 6:24 PM logoCytosorbents Corporation (NASDAQ:CTSO) Earns "Buy" Rating from Maxim Group - July 5 at 1:58 PM logoCytosorbents Corporation (CTSO) Receives Consensus Rating of "Buy" from Brokerages - July 4 at 12:32 AM logoCytosorbents: A Razor & Razor Blade Story - June 28 at 5:31 PM logoCytoSorbents Announces Director and Management Open Market Stock Purchases - June 15 at 6:30 PM logoCytosorbents Corporation (CTSO) Expected to Post Quarterly Sales of $3.29 Million - June 15 at 11:54 AM logoABIOMED (ABMD) and Cytosorbents Corporation (CTSO) Critical Survey - June 14 at 7:50 AM logoInsider Buying: Cytosorbents Corporation (CTSO) Insider Buys 2,500 Shares of Stock - June 13 at 9:02 PM logo-$0.06 Earnings Per Share Expected for Cytosorbents Corporation (CTSO) This Quarter - June 13 at 8:20 AM logoInsider Buying: Cytosorbents Corp (CTSO) Insider Purchases 3,700 Shares of Stock - June 8 at 8:20 PM logoCytosorbents Corp (CTSO) Now Covered by Analysts at Cowen and Company - June 7 at 8:32 PM logoCytosorbents Corp (CTSO) Given Consensus Recommendation of "Buy" by Brokerages - June 7 at 8:34 AM logoCytosorbents Corp (CTSO) Insider Phillip P. Chan Buys 6,300 Shares - June 6 at 8:41 PM logoCytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors - June 6 at 4:48 PM logoCytosorbents Corp (CTSO) & ABIOMED (ABMD) Critical Comparison - June 6 at 8:44 AM logoCytosorbents (CTSO) Names Dr. Eric G. Mortensen as Chief Medical ... - - May 30 at 9:55 PM logoDr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer - May 30 at 11:51 AM logoCytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference - May 24 at 12:40 PM logoCytosorbents Corp (CTSO) PT Set at $10.00 by Maxim Group - May 23 at 8:04 PM logoETFs with exposure to CytoSorbents Corp. : May 22, 2017 - May 22 at 4:22 PM logoAferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021 - May 22 at 12:16 PM logoCytosorbents Corp (CTSO) to Post Q2 2017 Earnings of ($0.07) Per Share, Zacks Investment Research Forecasts - May 17 at 8:00 AM logoZacks: Analysts Expect Cytosorbents Corp (CTSO) Will Announce Earnings of -$0.08 Per Share - May 16 at 4:04 PM logoResearch Analysts Issue Forecasts for Cytosorbents Corp's FY2020 Earnings (CTSO) - May 16 at 1:48 PM logoCTSO: Revenue Acceleration Expected 2H. REFRESH Efficacy Compelling - May 16 at 12:11 PM logoCytosorbents Corp (CTSO) Earns "Buy" Rating from B. Riley - May 15 at 7:34 PM logoCytosorbents Corp to Post Q2 2017 Earnings of ($0.06) Per Share, B. Riley Forecasts (CTSO) - May 11 at 9:26 AM logoCytosorbents Corp (CTSO) Given "Buy" Rating at B. Riley - May 10 at 9:30 PM logoCytoSorbents Corp. :CTSO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 - May 10 at 4:45 PM logoETFs with exposure to CytoSorbents Corp. : May 9, 2017 - May 9 at 9:33 PM logoCytosorbents Corp (CTSO) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - May 9 at 1:38 PM logoCytosorbents Corp (CTSO) Given "Buy" Rating at Aegis - May 9 at 10:26 AM logoCytoSorbents Reports First Quarter 2017 Financial Results - May 8 at 9:25 PM logoCytoSorbents reports 1Q loss - May 8 at 9:25 PM logoInvestor Network: CytoSorbents Corporation to Host Earnings Call - May 8 at 4:25 PM logoCytosorbents Corp's (CTSO) "Buy" Rating Reiterated at B. Riley - May 6 at 5:08 PM logoCytosorbents (CTSO) Presents REFRESH I Trial Results at AATS - - May 5 at 9:48 PM logoCytoSorbents Announces Positive REFRESH I Trial Results - May 5 at 4:47 PM logoCytoSorbents to Report Q1 2017 Operating and Financial Results - May 2 at 7:57 PM logoCytosorbents Corp (CTSO) Receives Media Sentiment Score of 0.44 - May 2 at 12:56 PM logoCytosorbents Corp (CTSO) Earns Coverage Optimism Score of 0.05 - April 29 at 2:51 PM logoZacks: Brokerages Anticipate Cytosorbents Corp (CTSO) Will Post Quarterly Sales of $2.99 Million - April 27 at 10:24 AM logoBiotech Forum Daily Digest: Biogen Kicks Off Earning Season In Style - Spotlight On Cytosorbents - April 27 at 1:58 AM logo-$0.11 Earnings Per Share Expected for Cytosorbents Corp (CTSO) This Quarter - April 26 at 12:03 AM



Cytosorbents Corp (CTSO) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff